U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07341919) titled 'Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases' on Dec. 13, 2025.
Brief Summary: his prospective, comparative pilot study investigates the safety and functional outcomes of subtenon autologous platelet-rich plasma (PRP) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with Pseudodrusen-like Appearance (EMAP).
Participants will receive three subtenon injections of autologous platelet-rich plasma (1.5 mL per injection) administered at two-month intervals (M0, M2, M4).
The primary objective is to assess functional changes over a 6-month period, with a focus on visual fi...